Orlistat: a comprehensive review of a lipase inhibitor from obesity management to emerging oncological applications
Li Li, Yuchao Hao · 2026
Read Orlistat: a comprehensive review of a lipase inhibitor from obesity management to emerging oncological applications by Li Li, Yuchao Hao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13621131.txt.
Description
Li Li and Yuchao Hao review a weight-loss drug's second life in a 2026 paper. The drug blocks fat-digesting enzymes in the gut and has anchored obesity care for over two decades, trimming fat absorption and aiding modest weight loss. It also improves blood sugar control and heart risk factors. Its gut side effects, though predictable, often erode patient adherence.
Lab studies found the drug also blocks a fat-building enzyme that many cancers overuse. In cancer models it triggered cell death, stalled the cell cycle, and boosted immunotherapy. The authors weigh the promise and caution that cancer use is still early-stage.
Catalog record
| CREATOR | Li Li, Yuchao Hao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 54 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |